Novartis (NYSE:NVS) division Sandoz and Pear Therapeutics this week kicked off the U.S. commercial launch of the first FDA-cleared prescription digital therapy for people with opioid use disorder.
The companies partnered to commercialize a 12-week cognitive behavioral therapy intended to be used in tandem with outpatient treatment. The therapy includes transmucosal buprenorphine and contingency management designed to reinforce positive behaviors, the companies reported.
Get the full story at our sister site, Drug Delivery Business News.
The post Sandoz, Pear launch digital therapy for opioid use disorder appeared first on MassDevice.